Evidence map›Paper›PMID 36792805›Full record

Trial reportInvestigational new drugs2023

Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.

Markus Joerger, Thomas Hundsberger, Simon Haefliger, Roger von Moos, Andreas F Hottinger, Thomas Kaindl, Marc Engelhardt, Michalina Marszewska, Heidi Lane, Patrick Roth and 1 more

Registry-linked trialOpen access · hybridAbstract readMulticenter StudyClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Investigational new drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02895360 (An Open-label Phase 1/2a Study of BAL101553 Administered as Intravenous 48-hour Infusions in Adult Patients With Advanced Solid Tumors or Recurrent Glioblastoma), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02895360 phase1 / phase2completednot on this map

An Open-label Phase 1/2a Study of BAL101553 Administered as Intravenous 48-hour Infusions in Adult Patients With Advanced Solid Tumors or Recurrent Glioblastoma

TypeinterventionalSponsorBasilea PharmaceuticaRan2016 to 2020Enrolled43ConditionsNeoplasmsArmsBAL101553, BAL101553 at MTD
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Markus JoergerDepartment of Hematology/Oncology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Thomas HundsbergerDepartment of Hematology/Oncology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Simon HaefligerDepartment of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Roger von MoosDepartment of Medical Oncology/Hematology, Cantonal Hospital Graubünden, Chur, Switzerland.
Andreas F HottingerLundin Family Brain Tumor Research Center, Departments of Oncology & Clinical Neurosciences, Lausanne University Hospital & University of Lausanne, Lausanne, Switzerland.
Thomas KaindlBasilea Pharmaceutica International Ltd, Hegenheimermattweg 167b, Allschwil, 4123, Switzerland. Thomas.Kaindl@basilea.com.
Marc EngelhardtBasilea Pharmaceutica International Ltd, Hegenheimermattweg 167b, Allschwil, 4123, Switzerland.
Michalina MarszewskaBasilea Pharmaceutica International Ltd, Hegenheimermattweg 167b, Allschwil, 4123, Switzerland.
Heidi LaneBasilea Pharmaceutica International Ltd, Hegenheimermattweg 167b, Allschwil, 4123, Switzerland.
Patrick RothDepartment of Neurology and Brain Tumor Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Anastasios StathisOncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland.
Basilea Pharmaceutica (Switzerland) · CHUniversity of St.Gallen · CHInstitute of Oncology Research · CHKantonsspital Graubünden · CHUniversity of Bern · CHUniversity of Lausanne · CHUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLisavanbulin (BAL101553) is the prodrug of avanbulin (BAL27862), a microtubule-destabilizing agent. The goal of this study (NCT02895360) was to characterize the safety, tolerability and antitumor activity of lisavanbulin administered as a 48-hour intravenous (IV) infusion at the recommended Phase 2 dose (RP2D) of 70 mg/m

Indexed as

GlioblastomaOvarian NeoplasmsBenzimidazolesFemaleHumansNeoplasm Recurrence, LocalOxadiazolesBenzimidazoleslisavanbulinOxadiazolesAvanbulinBAL101553GlioblastomaLisavanbulinMicrotubule-targeting agent

Identifiers

PMID36792805
PMCPMC10140113
OpenAlexW4320881625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.